Identifying bromazolam, etizolam, and flualprazolam in blood using gas chromatography–mass spectrometry
- 18 February 2025
- journal article
- Published by Wiley in Journal of Forensic Sciences
- Vol. 70 (3) , 1105-1113
Abstract
Designer benzodiazepines are a commonly misused class of novel psychoactive substances (NPS) that present challenges for forensic toxicology laboratories and public health. Due to the difficulty in detection by routine toxicology methods, it is important to enhance the analytical methods for the identification and quantitation of designer benzodiazepines. The aim of this study was to identify and quantify designer benzodiazepines using gas chromatography coupled with mass spectrometry (GC‐MS) in postmortem blood specimens. A method originally validated to identify and quantitate alprazolam was modified to quantitate flualprazolam, etizolam, and bromazolam, as well as identify adinazolam and 4′‐chloro‐deschloroalprazolam. The method was subsequently used to analyze postmortem specimens (n = 35) from Medical Examiner Districts (n = 4) in Florida that screened positive for one or more designer benzodiazepines from February 2022 to December 2023. Among the screened samples, 21 tested positive for one or more designer benzodiazepines in the postmortem blood; 1 was positive for etizolam (90 ng/mL) and flualprazolam (<5.0 ng/mL), while 20 were positive for bromazolam. Bromazolam was the most frequently detected designer benzodiazepine, with a concentration range of 5.9–352 ng/mL (mean: 59.1 ng/mL; median: 28.5 ng/mL) for 18 decedents and <5.0 ng/mL for two decedents. Polydrug use was confirmed in all decedents. The most prevalent drugs found with bromazolam in the blood were fentanyl, methamphetamine and/or amphetamine, and cocaine. The optimized GC‐MS method provides a way to identify and quantitate designer benzodiazepines in postmortem blood and to also qualitatively monitor two newer designer benzodiazepines: 4′‐chloro‐deschloroalprazolam and adinazolam.Keywords
This publication has 28 references indexed in Scilit:
- A strategy for the detection of benzodiazepine drugs using low‐resolution paper‐spray mass spectrometry for harm reduction drug checkingDrug Testing and Analysis, 2023
- Post mortem blood bromazolam concentrations and co-findings in 96 coronial cases within England and WalesForensic Science International, 2023
- The sentinel role of forensic toxicology laboratories to identify and act upon diverse drug threats by addressing toxicology and economic demandsForensic Science International: Synergy, 2022
- The alprazolam analogue 4′‐chloro deschloroalprazolam identified in seized capsulesDrug Testing and Analysis, 2022
- Femoral blood concentrations of flualprazolam in 33 postmortem casesForensic Science International, 2020
- Development of a sensitive untargeted liquid chromatography–high resolution mass spectrometry screening devoted to hair analysis through a shared MS2 spectra database: A step toward early detection of new psychoactive substancesDrug Testing and Analysis, 2018
- Development and application of a multi-component LC–MS/MS method for determination of designer benzodiazepines in urineJournal of Chromatography B, 2016
- Analysis of phenazepam and 3‐hydroxyphenazepam in post‐mortem fluids and tissuesDrug Testing and Analysis, 2015
- Overdose of Etizolam: The Abuse and Rise of a Benzodiazepine AnalogAnnals of Emergency Medicine, 2015
- Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokineticsDrug Testing and Analysis, 2014